SCHEMBL3783557

SCHEMBL3783557

O=C(O)N1C=Cc2ccccc2O1

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 5/20 0.33
ATM Q13315 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
POLB P06746 1/20 0.32
CASP6 P55212 1/20 0.32
CYP2C9 P11712 1/20 0.32
LMNA P02545 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
SCN4A P35499 1/20 0.32
SCN5A Q14524 1/20 0.32
SCN9A Q15858 1/20 0.32
HTR2C P28335 1/20 0.30
HTR2B P41595 1/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5999468 0.84 LMNA (0.42) P2RX4ATMMEN1KMT2ACYP2C9
SCHEMBL11772116 0.80 PTPN1 (0.32) MEN1KMT2A
SCHEMBL16823583 0.74 CA12 (0.40) MEN1KMT2APOLBCYP2C9LMNA
SCHEMBL1491181 0.72 KDM4E (0.33) MEN1KMT2AHTR2CHTR2BKDM4E
SCHEMBL26686708 0.70 CYP2C9 (0.33) P2RX4MEN1KMT2APOLBCASP6
SCHEMBL15201897 0.69 HTR2C (0.32) MEN1KMT2AHTR2CHTR2BKDM4E
SCHEMBL7503770 0.68 SLC7A5 (0.39) KDM4E
SCHEMBL3342528 0.68 KDM4E (0.37) MEN1KMT2AHTR2CHTR2BKDM4E
SCHEMBL22115886 0.68 KDM4E (0.33) MEN1KMT2AHTR2CHTR2BKDM4E
SCHEMBL1661412 0.68 BRD4 (0.34) MEN1KMT2ATSHRMAPK1HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618977-B2 Method of treating dermatitis comprising administering a chymase inhibitor ASUBIO PHARMA CO., LTD. (JP) 2009-11-17 US claimed
EP-1174151-B1 THERAPEUTIC TREATMENT OF EOSINOPHILIA USING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT DAIICHI ASUBIO PHARMA CO LTD (JP) 2007-01-24 EP claimed
US-6677344-B2 Chymase inhibitor for the treatment of eosinophilia DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2004-01-13 US claimed
US-6500835-B2 FOR PROPHYLAXIS AND THERAPY OF FIBROSIS INVOLVING EXTRACELLULAR MATRIX DYSBOLISM HAVING A CHYMASE INHIBITOR AS AN EFFECTIVE INGREDIENT; SIDE EFFECT REDUCTION SUNTORY LIMITED (JP) 2002-12-31 US claimed
WO-2000063215-A2 INDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI-SYNTHELABO (FR) 2000-10-26 WO claimed
EP-1025109-A1 BENZOXAZINE DERIVATIVES, PREPARATION AND APPLICATION IN THERAPY SANOFI-SYNTHELABO (FR) 2000-08-09 EP claimed
WO-1999020633-A1 BENZOXAZINE DERIVATIVES, PREPARATION AND APPLICATION IN THERAPY SANOFI-SYNTHELABO (FR) 1999-04-29 WO claimed
WO-2017038909-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-09 WO disclosed
CN-1980938-B Mitotic kinesin inhibitors MERCK & CO INC 2010-11-03 CN disclosed
US-20100029695-A1 METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR ASUBIO PHARMA CO., LTD. (JP) 2010-02-04 US disclosed
US-7618977-B2 Method of treating dermatitis comprising administering a chymase inhibitor ASUBIO PHARMA CO., LTD. (JP) 2009-11-17 US disclosed
US-7494992-B2 Antiparasitic terpene alkaloids PFIZER INC. (US) 2009-02-24 US disclosed
US-20070185101-A1 Antiparasitic terpene alkaloids PFIZER PRODUCTS INC 2007-08-09 US disclosed
EP-1142586-A1 INHIBITORS AGAINST VASCULAR LIPID DEPOSITION CONTAINING CHYMASE-INHIBITING SUBSTANCES SUNTORY LIMITED (JP) 2001-10-10 EP disclosed
EP-1114035-A1 QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF SUNTORY LIMITED (JP) 2001-07-11 EP disclosed
WO-2000063215-A2 INDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI-SYNTHELABO (FR) 2000-10-26 WO disclosed
EP-1025109-A1 BENZOXAZINE DERIVATIVES, PREPARATION AND APPLICATION IN THERAPY SANOFI-SYNTHELABO (FR) 2000-08-09 EP disclosed
WO-2000010982-A1 QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEROF SUNTORY LIMITED (JP) 2000-03-02 WO disclosed
WO-1999020633-A1 BENZOXAZINE DERIVATIVES, PREPARATION AND APPLICATION IN THERAPY SANOFI-SYNTHELABO (FR) 1999-04-29 WO disclosed
US-5801023-A Antiparasitic pyrrolobenzoxazine compounds PFIZER INC. (US) 1998-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185101-A1 Antiparasitic terpene alkaloids CYP51A1, DHPS, CYP8B1 P2RX4 158/4885ATM 4875/4885MEN1 4383/4885
US-20100029695-A1 METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR CMA1, DNPEP, SERPINB1 P2RX4 1886/4885ATM 2441/4885MEN1 4531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.